MetLife, Inc. (MET) Stock Analysis 2026: Is MetLife a Good Investment?
 |
| MetLife, Inc. (MET) |
Worldreview1989 - MetLife, Inc. (NYSE: MET) is one of the largest insurance and financial-services companies in the United States, with businesses spanning life insurance, employee benefits, retirement and income solutions, annuities, asset management, and international insurance markets.
For U.S. investors, MET is particularly interesting because it combines dividend income, share repurchases, relatively strong recurring earnings, and exposure to higher investment income. However, investors should also understand that an insurer cannot be evaluated in the same way as a technology or consumer company.
The latest available market data puts MET around $97.62 per share, while the company reported strong second-quarter 2026 operating results. (MetLife)
Investment view: MetLife looks more attractive as a quality financial/dividend stock for long-term investors than as a high-growth stock. Its biggest strengths are earnings diversification, capital returns, underwriting performance, and investment income. Its principal risks are interest-rate movements, investment losses, insurance claims, capital requirements, and valuation after the stock's strong appreciation.
MetLife Stock Snapshot
| Metric | MET |
|---|---|
| Company | MetLife, Inc. |
| Ticker | NYSE: MET |
| Sector | Financial Services |
| Industry | Insurance |
| Latest price* | ~$97.62 |
| Market capitalization* | ~$62.0 billion |
| TTM P/E* | ~18.7x |
| TTM EPS* | ~$5.23 |
| Q2 2026 adjusted EPS | $2.43 |
| Q2 2026 adjusted ROE | 17% |
| Q2 2026 adjusted earnings | $1.6 billion |
| Q2 2026 PFOs | $13.7 billion |
| Q3 2026 common dividend | $0.5925/share |
*Market data shown as of September 4, 2026; valuation multiples can change with the share price.
MetLife's third-quarter 2026 common dividend is $0.5925 per share, following a 4.4% increase announced in April. (MetLife Investor Relations)
1. What Does MetLife Actually Do?
MetLife is much more than a traditional life insurer.
Its business model includes:
Group benefits
Life insurance
Retirement and income solutions
Annuities
Employee benefits
International insurance
Asset management
Institutional retirement products
The company operates in more than 40 markets globally. (MetLife)
This diversification matters because earnings don't depend on a single insurance product or geographic market.
For example, in Q2 2026:
Group Benefits adjusted earnings rose 25%
Retirement & Income Solutions increased 2%
Asia increased 21%
Latin America increased 15%
EMEA increased 8%
MetLife Investment Management increased 6%. (MetLife)
That is one reason MET can appeal to investors who prefer a diversified financial company rather than a concentrated insurance business.
2. 2025 Financial Performance
MetLife's 2025 results provide a useful baseline before analyzing 2026.
According to MetLife's SEC filings, 2025 consolidated results included:
| Financial Metric | 2025 |
|---|---|
| Premiums | $49.78B |
| Universal life & investment-type fees | $5.00B |
| Net investment income | $22.56B |
| Other revenues | $2.83B |
| Total revenues | $77.08B |
| Total expenses | $72.42B |
| Net income | $3.40B |
| Net income attributable to MetLife | $3.38B |
| Net income available to common shareholders | $3.17B |
| Diluted EPS | $4.71 |
The SEC filing also shows that MetLife's total revenue increased from approximately $66.9 billion in 2023 to $71.0 billion in 2024 and $77.1 billion in 2025.
That represents substantial top-line expansion.
However, investors should be careful when interpreting insurance-company revenue.
Revenue growth does not automatically equal shareholder earnings growth.
Insurance companies can experience large changes in investment gains/losses, derivative results, policyholder liabilities, and other accounting items.
That is why MetLife emphasizes adjusted earnings and adjusted ROE alongside GAAP results.
3. 2026 Is Showing Strong Operating Momentum
This is probably the most important part of the current MET investment thesis.
MetLife's first-quarter 2026 results were strong.
The company reported:
Net income of $1.1 billion
Adjusted earnings of $1.6 billion
Adjusted EPS of $2.42
Adjusted EPS growth of 23%
Adjusted ROE of 17%
PFO growth of 5%
Adjusted PFO growth excluding PRT of 10%
Net investment income growth of 10%
More than $1.1 billion returned to shareholders. (MetLife)
Then Q2 continued the momentum.
MetLife reported:
Net income: $705 million
Adjusted earnings: $1.6 billion
Adjusted EPS: $2.43
Adjusted EPS growth: 20%
PFO growth: 7%
Net investment income growth: 18%
Adjusted ROE: 17%
Adjusted BVPS: $57.71
More than $1.1 billion returned to shareholders during the quarter. (MetLife)
For investors, the consistency is important.
MetLife wasn't dependent on just one favorable quarter.
Q1 and Q2 both produced adjusted ROE of 17%.
4. The Most Important Metric: Adjusted ROE
For an insurer such as MetLife, I would pay considerably more attention to return on equity (ROE) than simply looking at P/E.
Why?
An insurance company manages enormous amounts of capital and investments.
The question isn't simply:
"How much profit does MetLife make?"
The better question is:
"How efficiently is MetLife generating earnings from shareholder capital?"
MetLife reported an adjusted ROE of 17% in both Q1 and Q2 2026, which is at the upper end of the company's 15%-17% annual target range. (MetLife)
That is a strong signal.
A sustained ROE around the high teens can support:
Dividend growth
Share repurchases
Book-value growth
Reinvestment
Higher long-term intrinsic value
5. Why Higher Interest Rates Can Help MetLife
This is one of the most interesting elements of the MET thesis.
Insurance companies collect premiums today and may pay claims years or decades later.
That creates a large investment portfolio.
MetLife invests heavily in fixed-income assets, meaning interest rates can have an important impact on investment income.
MetLife's Q2 2026 results showed net investment income rising 18% to $6.7 billion. (MetLife)
Industry analysis has also highlighted how higher long-term yields can benefit large life insurers because their investment portfolios can generate greater income. (The Motley Fool)
But there is an important nuance.
Higher rates are not automatically bullish.
Higher rates can:
Increase new-money investment yields
Increase recurring investment income
Improve returns on newly invested premiums
But they can also:
Reduce the market value of existing bonds
Create mark-to-market volatility
Affect capital ratios
Increase economic pressure on certain policyholders or businesses
Therefore, the ideal environment for MET isn't necessarily "rates always rise."
A more attractive scenario is structurally higher yields combined with manageable volatility.
6. MetLife's Dividend Is a Major Part of the Investment Case
MetLife increased its common dividend by 4.4% in 2026, from $0.5675 to $0.5925 per quarter. (MetLife Investor Relations)
At $0.5925 per quarter, the annualized dividend is:
$0.5925 × 4 = $2.37 per share
At approximately $97.62 per share, the simple forward dividend yield is approximately:
2.43%
That is not an exceptionally high yield.
But investors shouldn't evaluate MET solely by current yield.
The more interesting combination is:
Dividend + share repurchases + earnings growth + book-value growth
MetLife returned nearly $4.4 billion to shareholders during 2025 through dividends and share repurchases. (MetLife)
Management also returned more than $1.1 billion in Q2 2026 and continued repurchasing common shares. (MetLife)
This creates a potentially attractive shareholder-return engine.
7. Share Buybacks Matter
Share repurchases are particularly interesting for MET because they can increase earnings per share even if total corporate earnings grow more slowly.
For example, imagine:
Net earnings grow 5%
Shares outstanding decline 3%
EPS can potentially grow faster than 5%.
MetLife's Q2 earnings release showed adjusted EPS growing 20%, compared with adjusted earnings growth of 15%, illustrating how capital management can contribute to per-share results. (MetLife)
For long-term investors, this distinction is important.
You don't own "MetLife earnings."
You own MetLife per-share economics.
8. Book Value Is Extremely Important for MET
Traditional P/E analysis can be misleading for financial companies.
Book value is therefore another important metric.
MetLife reported:
Q2 2026 BVPS: $38.59
Adjusted BVPS: $57.71
Adjusted BVPS increased 3% year over year, while reported BVPS increased 8%. (MetLife)
This gives investors another way to evaluate valuation.
At roughly $97.62, the stock trades at approximately:
Price / Reported Book Value
$97.62 ÷ $38.59 ≈ 2.53x
Price / Adjusted Book Value
$97.62 ÷ $57.71 ≈ 1.69x
The second number is arguably more useful for understanding MetLife's underlying operating economics, although investors should not treat adjusted book value as equivalent to GAAP book value.
9. What Are American Investors Likely to Like About MET?
Investor discussions around MetLife tend to focus on several recurring themes.
1. Dividend
Income investors appreciate the recurring dividend and the company's history of increasing shareholder distributions.
2. Buybacks
Investors like the fact that MetLife doesn't simply pay dividends; it also uses capital for share repurchases.
3. Diversification
MetLife's global operations and multiple business lines reduce dependence on a single product.
4. Higher investment income
Investors recognize that a large insurer can benefit from attractive yields on newly invested assets.
5. Less dependence on technology-stock valuations
MET is fundamentally different from high-growth technology stocks.
Its investment case is more closely connected to:
earnings
capital returns
book value
underwriting
interest rates
investment income
That can make it useful for portfolio diversification.
10. But What Do Investors Worry About?
The bullish case isn't risk-free.
Risk #1 — Investment portfolio losses
MetLife has hundreds of billions of dollars in investments.
The SEC's June 30, 2026 filing shows approximately $322.2 billion of fixed-maturity securities at estimated fair value. (SEC)
That creates substantial exposure to:
credit risk
interest-rate risk
commercial real estate
corporate bonds
structured securities
private assets
A deterioration in credit markets could negatively affect results.
Risk #2 — Variable investment income
MetLife's investment income includes variable components that can fluctuate.
Private equity and alternative investments can generate excellent returns during favorable markets but can also introduce earnings volatility.
Investors therefore shouldn't extrapolate one unusually strong quarter indefinitely.
Risk #3 — Insurance claims
MetLife is ultimately an insurance company.
Unexpected increases in:
mortality
morbidity
disability claims
catastrophic events
medical claims
can affect profitability.
This is why underwriting performance remains critical.
Risk #4 — Valuation
A good company can still be a bad investment if investors pay too much.
At approximately $97.62, MET is no longer trading near the depressed levels that historically made many insurers particularly attractive.
Recent market data also show the stock near its 52-week high. On September 3, 2026, MET closed around $99.23 after rising 2.91%, while its recent 52-week high was approximately $100.93. (MarketWatch)
That means investors should distinguish between:
"Is MetLife a good company?"
and
"Is MetLife cheap today?"
The answer to the first question looks increasingly favorable.
The answer to the second is more nuanced.
11. MET vs. Lincoln National
 |
| MetLife, Inc. (MET) |
One useful comparison for American investors is Lincoln National.
Recent analysis highlighted MetLife's larger scale and diversification, while Lincoln National offers a more aggressive turnaround profile and a higher dividend yield. (The Motley Fool)
| Factor | MetLife | Lincoln National |
|---|---|---|
| Scale | Very large | Smaller |
| Global diversification | Strong | More U.S.-focused |
| Business diversification | Strong | More concentrated |
| Dividend yield | Lower | Higher |
| Risk | Moderate | Higher |
| Growth profile | Balanced | Turnaround-oriented |
| Investor profile | Quality/income | Value/aggressive |
For a conservative long-term investor, MET appears easier to underwrite.
For a deep-value investor willing to accept greater risk, Lincoln National may offer a different opportunity.
12. MET Valuation: Is the Stock Expensive?
Using the current share price around $97.62 and TTM EPS around $5.23, MET's trailing P/E is roughly 18.7x.
However, using insurer-specific measures gives a different perspective.
The 2025 annual results produced diluted GAAP EPS of $4.71, while MetLife reported 2025 adjusted EPS of $8.89 excluding total notable items. (MetLife)
That difference demonstrates why a simple trailing P/E can make an insurer look more expensive than its underlying operating earnings suggest.
A better valuation framework for MET is:
Conservative approach
Adjusted EPS
Adjusted ROE
Adjusted book value
Dividend
Buybacks
More aggressive approach
Future EPS growth
Normalized investment income
Higher ROE
Book-value compounding
13. My MET Fair-Value Framework
Rather than pretending that there is one precise intrinsic value, I prefer a valuation range.
Bear case
$75–$85
This could occur if:
investment income deteriorates
interest-rate volatility increases
underwriting weakens
alternative investments disappoint
ROE falls substantially
Base case
$90–$105
This assumes:
adjusted ROE remains around the mid-to-high teens
earnings continue growing moderately
dividends continue increasing
buybacks remain meaningful
investment income remains healthy
Bull case
$110–$125+
This scenario requires:
sustained strong earnings growth
continued 17%+ adjusted ROE
strong investment income
continued capital returns
favorable valuation expansion
These are scenario estimates, not price targets from MetLife or a guarantee of future returns.
14. What Makes MET Different From a Typical Dividend Stock?
A common mistake is to compare MetLife with companies such as Coca-Cola, Procter & Gamble, or Verizon simply because all pay dividends.
MetLife is fundamentally different.
Its earnings are influenced by:
Insurance premiums → investment assets → investment income → claims → reserves → capital → shareholder returns
This creates a much more complicated financial model.
For this reason, MET investors should monitor:
Adjusted EPS
Adjusted ROE
Premiums, fees and other revenues
Net investment income
Variable investment income
Book value per share
Capital ratios
Share repurchases
Dividend growth
Underwriting results
15. MetLife's Balance Sheet Deserves Attention
MetLife's financial strength is one of the most important reasons investors own the stock.
As of June 30, 2026, the company reported substantial fixed-maturity investments and a large overall asset base. Its SEC Form 10-Q also provides detailed disclosures regarding policyholder liabilities, investments, derivatives and capital structure. (SEC)
At the holding-company level, MetLife reported:
$3.4 billion of cash and liquid assets
at the end of Q2 2026, within its targeted $3 billion-$4 billion liquidity buffer. (MetLife)
Management also reported estimated U.S. statutory adjusted capital of approximately $16.4 billion at June 30, 2026. (The Motley Fool)
For an insurance company, capital strength is fundamental.
16. MetLife's New Frontier Strategy
MetLife is currently operating under its New Frontier strategy.
The company describes the strategy around:
balanced growth
improving returns
disciplined expense management
capital deployment
global diversification
customer-centric growth
The early results are encouraging.
In 2025, MetLife achieved:
10% adjusted EPS growth
16% adjusted ROE
10% PFO growth
nearly $4.4 billion returned to shareholders. (MetLife)
Then in 2026, the company maintained a 17% adjusted ROE in both Q1 and Q2. (MetLife)
That gives investors evidence that the strategy isn't purely a management presentation.
17. MET Investment Thesis for 2026
Bullish factors
+ Strong adjusted earnings growth
Q2 adjusted EPS rose 20%.
+ Excellent ROE
Adjusted ROE remained at 17%.
+ Strong investment income
Q2 net investment income rose 18%.
+ Dividend growth
The quarterly dividend increased 4.4%.
+ Share repurchases
Buybacks enhance per-share earnings and shareholder returns.
+ Global diversification
MetLife operates across more than 40 markets.
+ Strong capital position
Liquidity and statutory capital remain important strengths.
Bearish factors
− Stock price has already appreciated significantly
The valuation is less obviously cheap than it was at lower prices.
− Investment portfolio risk
Large fixed-income and alternative-investment exposure creates market and credit risks.
− Insurance risk
Claims and underwriting experience can change.
− Interest-rate sensitivity
Rates affect both investment income and asset valuations.
− Earnings volatility
GAAP earnings can differ substantially from normalized operating performance.
18. What American Readers Should Ask Before Buying MET
Before buying MetLife, I would ask five questions:
1. Is the adjusted ROE still around 15%-17%?
If yes, the business remains highly productive.
2. Is adjusted EPS continuing to grow?
This determines whether the current valuation can be justified.
3. Is book value per share increasing?
Long-term book-value growth is an important indicator of financial-company value creation.
4. Is MetLife returning excess capital responsibly?
Dividends and buybacks should ideally be funded by sustainable earnings and capital generation.
5. Is the stock price providing an adequate margin of safety?
Even an excellent insurer can produce poor returns when purchased at an excessive valuation.
19. My Overall MET Stock Rating
| Category | Rating |
|---|---|
| Business quality | 8.5/10 |
| Financial strength | 8.5/10 |
| Earnings momentum | 9/10 |
| Dividend quality | 8/10 |
| Capital allocation | 8.5/10 |
| Growth potential | 7.5/10 |
| Valuation | 7/10 |
| Risk | 7/10 |
| Overall | 8.1/10 |
Investment profile
MET is not a "get rich quick" stock.
It is better viewed as a large-cap financial compounder with dividend income and shareholder capital returns.
The strongest argument for MET is not simply its dividend.
The stronger argument is:
High-teens adjusted ROE + earnings growth + investment income + dividend growth + share repurchases + global diversification.
20. Final Verdict: Is MetLife Stock a Buy?
For a long-term U.S. investor, I consider MetLife one of the more interesting large-cap insurance stocks to monitor in 2026.
The company's latest results are encouraging. Q2 adjusted earnings reached $1.6 billion, adjusted EPS rose 20%, adjusted ROE remained at 17%, investment income increased 18%, and MetLife continued returning significant capital to shareholders. (MetLife)
The biggest issue is price.
At around $97.62, investors are no longer buying an overlooked insurance stock at a distressed valuation. The stock has moved substantially higher and was recently close to its 52-week high. (MarketWatch)
Therefore, my framework is:
Below $85
Potentially attractive / strong margin of safety
$85–$95
Attractive for long-term accumulation
$95–$105
Reasonable / Hold or accumulate gradually
$105–$115
More valuation-sensitive
Above $115
Requires stronger earnings growth to justify the valuation
In other words, I would not chase MET aggressively after a major rally. For investors who already own it, however, the combination of earnings growth, 17% adjusted ROE, dividends and buybacks provides a credible long-term holding thesis.
Bottom Line
MetLife (NYSE: MET) looks more like a quality compounder and income stock than a deep-value stock in 2026.
Its strongest characteristics are:
Strong capital position → diversified insurance operations → growing investment income → high ROE → dividend growth → buybacks → per-share earnings growth.
The main risks are:
investment losses → interest-rate volatility → insurance claims → capital requirements → valuation compression.
For a diversified U.S. portfolio, MET can make sense as a financial-sector/dividend holding, particularly for investors who are comfortable with insurance-company accounting and balance-sheet risks.
Investor conclusion: BUY/ACCUMULATE on reasonable valuation; HOLD if already owned; avoid chasing the stock solely because of recent momentum.
This article is educational analysis, not individualized investment advice. Investors should review MetLife's SEC filings and their own risk tolerance before making an investment decision.
Primary and authoritative sources
Reader-sentiment context: investor discussions tend to emphasize MET's dividend, capital returns and value characteristics, while professional commentary has increasingly focused on its ROE, investment income and valuation. These opinions are supplementary; the financial conclusions above are based primarily on MetLife's own disclosures and SEC filings. (reddit.com)
About the Author
David Mulyana is the founder and editor of WorldReview1989, an independent publication dedicated to finance, investing, insurance, business, technology, and digital marketing.
He researches and writes in-depth articles that help readers understand complex financial topics through clear explanations, practical insights, and data-driven analysis. His editorial focus includes stock market investing, cryptocurrencies, banking, personal finance, business insurance, real estate, startup strategies, and emerging technology trends.
Every article published on WorldReview1989 is created with a commitment to accuracy, transparency, and reader value. Content is reviewed regularly to reflect the latest market developments, industry updates, and publicly available information from trusted sources.
Editorial Principles
- Accuracy before speed
- Independent and unbiased analysis
- Clear, easy-to-understand explanations
- Information supported by reputable public sources
- Regular updates to maintain content relevance
Areas of Expertise
- Personal Finance
- Investing & Stock Market
- Cryptocurrency & Blockchain
- Insurance
- Banking
- Real Estate
- Business & Entrepreneurship
- Digital Marketing
- Financial Technology (FinTech)
About WorldReview1989
WorldReview1989 provides educational content for readers seeking reliable information about finance, investment opportunities, insurance, business strategies, and technology. The website aims to simplify complex financial concepts and empower readers to make informed decisions.
Disclaimer: The information published on WorldReview1989 is for educational and informational purposes only. It should not be considered financial, legal, tax, or investment advice. Readers should consult qualified professionals before making financial decisions.
David Mulyana writes about stocks, financial markets, investment strategies, insurance and emerging-market opportunities, with a focus on helping readers understand financial data and investment risks
Join Facebook Group